Publications by authors named "T Tsuchikawa"
Introduction: Although neuroendocrine neoplasms (NENs) have a good prognosis, distant metastasis remains a crucial prognostic factor. Survivin, a tumor-associated antigen, is overexpressed in several solid tumors, indicating poor prognosis. We aimed to evaluate the clinical significance and role of survivin as a therapeutic target for NEN.
View Article and Find Full Text PDFIntroduction: Survival comparisons among patients with liver metastases from pancreatic and rectal neuroendocrine tumors (NETs) were limited, and the efficacy of observation rules in patients undergoing hepatectomy for neuroendocrine liver metastases (NELMs) was unknown. This study aims to distinguish these characteristics and clarify the effects of the observation rules on NELMs.
Methods: Clinical data were separately collected from patients with pancreatic and rectal NELMs at medical centers in both Japan and China.
Article Synopsis
- Researchers validated the NETest as a potential biomarker for gastroenteropancreatic neuroendocrine tumors (GEPNET) in Japanese patients between 2021 and 2023.
- A total of 35 patients participated, with the majority having pancreatic tumors, and 81.2% of blood samples were successfully tested using NETest.
- The NETest showed an impressive diagnostic sensitivity of 97.1% and effectively monitored disease progression in patients undergoing surgery and specialized therapy.
Toca 511, a tumor-selective retroviral replicating vector encoding the yeast cytosine deaminase (yCD) gene, exerts direct antitumor effects through intratumoral prodrug 5-fluorocytosine (5-FC) conversion to active drug 5-fluorouracil by yCD, and has demonstrated therapeutic efficacy in preclinical and clinical trials of various cancers. Toca 511/5-FC treatment may also induce antitumor immunity. Here, we first examined antitumor immune responses activated by Toca 511/5-FC treatment in an immunocompetent murine pancreatic cancer model.
View Article and Find Full Text PDFArticle Synopsis
- - CAR-T therapy shows great promise for treating blood cancers but struggles with solid tumors due to unique challenges related to tumor microenvironments.
- - This study utilized a mouse model of pancreatic ductal adenocarcinoma (PDAC) to investigate how CAR-T cells behave in solid tumors, revealing that these cells can actually persist and accumulate in PDAC tissues.
- - Despite their presence, CAR-T cells exhibited a gradual loss of effectiveness against the tumor over time, linked to changes in specific proteins associated with cell metabolism and function.